Moneycontrol
Get App
you are here: HomeNewsBusiness
Last Updated : Aug 23, 2019 10:53 AM IST | Source: PTI

Glenmark gets USFDA nod for generic breast cancer injection

The product is a generic version of AstraZeneca Pharmaceuticals LP's Faslodex Injection in the same strength, the company said in a statement.

Representative Image
Representative Image
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Glenmark Pharmaceuticals on Friday said its US arm has received the final approval from the US health regulator for its Fulvestrant injection used for the treatment of advanced breast cancer.

The product is a generic version of AstraZeneca Pharmaceuticals LP's Faslodex Injection in the same strength, the company said in a statement.

Glenmark Pharmaceuticals Inc USA has been granted final approval by the United States Food and Drug Administration (USFDA) for Fulvestrant injection in the strength of 250 mg/5 mL (50 mg/mL), it said.

Close

According to IQVIA sales data for the 12-month period ending June 2019, the Faslodex injection, 250 mg/5 mL (50 mg/mL) brand and and all available therapeutic equivalents achieved annual sales of approximately USD 549.9 million, Glenmark said.

The company's current portfolio consists of 159 products authorised for distribution in the US marketplace and 56 abbreviated new drug applications (ANDA's) pending approval with the USFDA, it added.

Shares of Glenmark Pharmaceuticals were trading at Rs 360.95 on BSE, up 0.39 percent from the previous close.

Get access to India's fastest growing financial subscriptions service Moneycontrol Pro for as little as Rs 599 for first year. Use the code "GETPRO". Moneycontrol Pro offers you all the information you need for wealth creation including actionable investment ideas, independent research and insights & analysis For more information, check out the Moneycontrol website or mobile app.
First Published on Aug 23, 2019 10:45 am
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant